Biologics & Biosimilars

Pharmaceutica 2019 includes Keynote and Speakers sessions on the most recent examination intended to offer extensive worldwide exchanges that address current issues in Pharmaceutica 2019.


Biologics are medicines made from living cells through highly complex manufacturing processes and must be handled and administered under carefully monitored conditions. Biologics are used to prevent, treat, diagnose, or cure a variety of diseases including cancer, chronic kidney disease, autoimmune disorders, and infectious diseases. Euro Biosimilars is exactly what its name implies — it is a biologic that is “similar” to another biologic drug already approved by the FDA. Under U.S. law, a biosimilar is approved based on a showing that it is “highly similar” to an FDA-approved biological product, known as a reference product. It may not have any clinically meaningful differences in terms of safety and effectiveness from the reference product.

  • Bio-analytics for biosimilars
  • Extrapolation and interchangeability
  • Legal considerations for biosimilars
  • Biosimilar uptake and market considerations
  • Challenges and regulatory approach for biosimilars
  • Future of next-generation biosimilars

 

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.